
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc has demonstrated strong financial performance with significant year-over-year sales growth since its acquisitions, particularly noting a 33% increase in sales for Giapreza from 2023 to 2024. Xerava, another key product, has maintained an impressive annual sales growth rate of over 20%, highlighting the success of the company's strategic portfolio management. Overall, since acquiring these assets in the third quarter of 2022, annualized run rates for both Giapreza and Xerava have nearly doubled, indicating robust market demand and effective integration within Innoviva’s operations.
Bears say
Innoviva Inc. faces a challenging financial outlook, primarily due to projected average year-over-year declines in royalties from GSK for its key products, Relvar/Breo and Anoro, estimated at -8% and -4% respectively over the next eight years. The company's revenue trajectory is further complicated by the anticipated loss of exclusivity for Giapreza in 2034, which may significantly impact future income streams. Additionally, concerns regarding the efficacy and limited use of colistin against multi-drug-resistant strains may further jeopardize the company's performance within its critical care and infectious disease operating assets.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares